(19)
(11) EP 3 968 985 A1

(12)

(43) Date of publication:
23.03.2022 Bulletin 2022/12

(21) Application number: 20806609.2

(22) Date of filing: 14.05.2020
(51) International Patent Classification (IPC): 
A61K 31/4155(2006.01)
A61K 31/395(2006.01)
C07K 16/28(2006.01)
 A61K 31/5355(2006.01)
C07D 413/14(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2317/31; C07K 16/2863; A61K 39/39558; A61P 35/00; C07K 2317/73; A61K 45/06; A61K 31/5377; A61K 31/517; A61K 31/506
 
C-Sets:
  1. A61K 39/39558, A61K 2300/00;
  2. A61K 31/5377, A61K 2300/00;
  3. A61K 31/517, A61K 2300/00;
  4. A61K 31/506, A61K 2300/00;
(86) International application number:
PCT/IB2020/054594
(87) International publication number:
WO 2020/230091 (19.11.2020 Gazette 2020/47)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 14.05.2019 US 201962847605 P

(71) Applicant: Janssen Biotech, Inc.
Horsham, PA 19044 (US)

(72) Inventors:
  • LAQUERRE, Sylvie
    Spring House, Pennsylvania 19477 (US)
  • LORENZI, Matthew
    Spring House, Pennsylvania 19477 (US)
  • MOORES, Sheri
    Spring House, Pennsylvania 19477 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND THIRD GENERATION EGFR TYROSINE KINASE INHIBITORS